Targeting Chronic Cerebral Toxoplasmosis in Immunocompromised Hosts: In Vivo Antiparasitic and Immuno-Apoptotic Effects of Phellandrene Combined with Pyrimethamine
Vector-Borne and Zoonotic Diseases · 2026
DOI: 10.1177/15303667261474977 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vector-Borne and Zoonotic Diseases, 2026. Verfasst von Saeed M N Alasmari und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Faculty of Science and Arts, Najran University, Najran, Saudi Arabia. Hauptthemen laut MEDLINE: Toxoplasmosis, Cerebral, Immunocompromised Host, Pyrimethamine, Antiprotozoal Agents. Die Arbeit nennt 44 Literaturangaben.
Abstract (Originalsprache)
Introduction
This investigation was conducted to assess the in vivo effects and potential mechanisms of action of phellandrene (PR) and pyrimethamine (PYM) combination therapy in the context of chronic cerebral toxoplasmosis in immunocompromised (ICM) murine models.
Methods
BALB/c dexamethasone-induced ICM mice infected with the Toxoplasma gondii ME49 strain were treated with PR (10 and 20 mg/kg) alone or in combination with PYM for 2 weeks. The number and diameter of tissue cysts, oxidant/antioxidant markers, cell-mediated immunity indicators ( e.g., interferon‐gamma [ IFN‐γ ], interleukin-12 [ IL-12 ], IL-4 ), apoptosis-related genes ( e.g., Caspase-3, BAX, and Bcl-2 ), and pathogenesis-related genes (serine protease inhibitor [serpin A3k] and bradyzoite surface antigen 1 [BAG1]) were examined by qRT-PCR.
Results
PR, principally in combination with PYM, reduced the load (26.6 cysts) and size (23.4 µm) of tissue cysts, modulated lipid peroxidation (2.36 nmol/mg tissue), glutathione peroxidase (5.31 U/mg tissue), and superoxide dismutase (47.4 U/mg tissue), and significantly elevated ( p < 0.001) the expression levels of cytokines ( IFN‐γ = 4.12-fold change, IL-12 = 3.91-fold change, and IL-4 = 1.24-fold change) and apoptosis genes ( Caspase-3 = 3.1-fold change, BAX = 3.89-fold change, and Bcl-2 = 1.17-fold change), while altering the expression of BAG1 (1.28-fold change) and serpin A3k (3.46-fold change).
Conclusion
In summary, PR, particularly in combination with PYM, demonstrated significant therapeutic efficacy against chronic toxoplasmosis in ICM mice. This effect appears to be mediated through modulation of oxidative stress, enhancement of antioxidant defenses, regulation of apoptosis, and improvement of host immune responses. Importantly, no significant toxicity was observed in vital organs. These findings highlight PR as a promising adjunct candidate; however, further pharmacokinetic and clinical investigations are required to confirm its translational potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Faculty of Science and Arts, Najran University, Najran, Saudi Arabia.
- Department of Biology, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia.
Zitieren
APA
Alasmari, S. M. N., & Alatawi, A. (2026). Targeting Chronic Cerebral Toxoplasmosis in Immunocompromised Hosts: In Vivo Antiparasitic and Immuno-Apoptotic Effects of Phellandrene Combined with Pyrimethamine. Vector-Borne and Zoonotic Diseases. https://doi.org/10.1177/15303667261474977
Vancouver
Alasmari SMN, Alatawi A. Targeting Chronic Cerebral Toxoplasmosis in Immunocompromised Hosts: In Vivo Antiparasitic and Immuno-Apoptotic Effects of Phellandrene Combined with Pyrimethamine. Vector-Borne and Zoonotic Diseases. 2026. doi:10.1177/15303667261474977
BibTeX
@article{Alasmari2026,
author = {Alasmari, Saeed M N and Alatawi, Aishah},
title = {Targeting Chronic Cerebral Toxoplasmosis in Immunocompromised Hosts: In Vivo Antiparasitic and Immuno-Apoptotic Effects of Phellandrene Combined with Pyrimethamine},
journal = {Vector-Borne and Zoonotic Diseases},
year = {2026},
doi = {10.1177/15303667261474977}
}
EUVIMED